AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10372238 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fenfluramine three times a day and 37.5 mg phentermine daily (n = 23)
Number of subjects: 44
Study 10372238 — intervention group
Group type: COMPARATOR
Intervention: Dual placebos (n = 21)
Number of subjects: 44
Study 9092419 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100-300 mg/day)
Number of subjects: 0
Study 9092419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 0
Study 9092419 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (for primary prevention)
Number of subjects: 0
Study 9092419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 1931470 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with non-micronised glibenclamide (2.5 mg)
Number of subjects: 13
Study 1931470 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (850 mg) with micronised glibenclamide (1.75 mg)
Number of subjects: 13
Study 1931470 — intervention group
Group type: COMPARATOR
Intervention: Water only (150 ml) with micronised glibenclamide (1.75 mg)
Number of subjects: 13
Study 1931470 — intervention group
Group type: COMPARATOR
Intervention: Water only (150 ml) with non-micronised glibenclamide (2.5 mg)
Number of subjects: 13
Study 6799077 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg four times a day
Number of subjects: 560
Study 6799077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 6799077 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 560
Study 31860632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzydamine
Number of subjects: 60
Study 31860632 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 60
Study 31860632 — intervention group
Group type: COMPARATOR
Intervention: Oral flurbiprofen
Number of subjects: 60
Study 30373095 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed hard palate closure (DHPC) protocol
Number of subjects: 64
Study 30373095 — intervention group
Group type: COMPARATOR
Intervention: Complete palatoplasty
Number of subjects: 64
Study 27797992 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral templates for 4 diagnostic groups (dyspepsia, suspected colorectal cancer, chest pain, chronic obstructive pulmonary disease) with intermittent surgery visits by study personnel.
Number of subjects: 500
Study 27797992 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral templates intervention group
Number of subjects: 500
Study 27797992 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard referral practice)
Number of subjects: 500
Study 25128052 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment as usual (7 days)
Number of subjects: 0
Study 25128052 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assisted discharge (3 days in hospital followed by treatment at home)
Number of subjects: 0
Study 25128052 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributes of early assisted discharge
Number of subjects: 0
Study 22054782 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ combination therapy
Number of subjects: 91
Study 22054782 — intervention group
Group type: COMPARATOR
Intervention: High-dose amlodipine monotherapy
Number of subjects: 91
Study 18949456 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based regimen (n = 96) with propofol as required, for a maximum of 10 days.
Number of subjects: 205
Study 18949456 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimens (n = 109) of propofol, midazolam or lorazepam combined with fentanyl or morphine.
Number of subjects: 205
Study 17125957 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered contraceptive counseling (n = 20)
Number of subjects: 41
Study 17125957 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (n = 21)
Number of subjects: 41
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (cream)
Number of subjects: 60
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (ointment)
Number of subjects: 60
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate (cream)
Number of subjects: 60
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate (ointment)
Number of subjects: 60
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (cream)
Number of subjects: 60
Study 16372801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (ointment)
Number of subjects: 60
Study 16372801 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate
Number of subjects: 60
Study 12126262 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 12126262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10868615 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose miconazole nitrate (1200 mg) vaginal ovule
Number of subjects: 558
Study 10868615 — intervention group
Group type: COMPARATOR
Intervention: Monistat 7 (miconazole nitrate 2%) Vaginal Cream
Number of subjects: 558
Study 8800024 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-slice, 3 mm slice thickness protocol
Number of subjects: 324
Study 8800024 — intervention group
Group type: EXPERIMENTAL
Intervention: New 6 mm slice thickness protocol
Number of subjects: 324
Study 8800024 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-slice, 3 mm slice thickness protocol
Number of subjects: 324
Study 8800024 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-slice, 6 mm slice thickness protocol
Number of subjects: 324
Study 1425900 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam suppository (20 mg)
Number of subjects: 24
Study 4025494 — intervention group
Group type: EXPERIMENTAL
Intervention: Social activation program (experimental group)
Number of subjects: 60
Study 4025494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30986738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (n = 76)
Number of subjects: 152
Study 30986738 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 76)
Number of subjects: 152
Study 30348185 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCT (800 mg daily)
Number of subjects: 38
Study 30348185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27425566 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Class Exchange Program (ECEP)
Number of subjects: 322
Study 27425566 — intervention group
Group type: COMPARATOR
Intervention: Control group (social‐emotional learning program)
Number of subjects: 322
Study 24134922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay for Performance (P4P) intervention, introduced in 2004, with bonus payments for physicians meeting qualifying scores on Clinical Performance Vignettes (CPVs).
Number of subjects: 0
Study 22840413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block with 20 mL of 0.5% ropivacaine with epinephrine 1:200,000
Number of subjects: 58
Study 22840413 — intervention group
Group type: COMPARATOR
Intervention: No TAP block (control group)
Number of subjects: 58
Study 22453346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer trainer
Number of subjects: 22
Study 22453346 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 22
Study 18230831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 500 mg administered intravenously over three consecutive days, in four cycles at 4 weekly intervals (total 6 g of MP).
Number of subjects: 15
Study 18230831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) administered intravenously over three consecutive days, in four cycles at 4 weekly intervals.
Number of subjects: 15
Study 15851425 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Infant (625 mg in 225 ml milk)
Number of subjects: 20
Study 15851425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol and Solvito N, 625 mg in 225 ml milk)
Number of subjects: 20
Study 15320475 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (selective ET-A and non-selective ET-A/B receptor antagonists)
Number of subjects: 0
Study 15320475 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 0
Study 15320475 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drugs targeting endothelin system
Number of subjects: 0
Study 10400482 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg/day beta-carotene for 1 week
Number of subjects: 38
Study 10400482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8712397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane anesthesia
Number of subjects: 100
Study 8712397 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 100
Study 1810525 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (100 mg)
Number of subjects: 20
Study 1810525 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam-beta-cyclodextrin (20 mg)
Number of subjects: 20
Study 29884132 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-OTSA-101
Number of subjects: 20
Study 29884132 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-OTSA-101 (Arm A: 370 MBq)
Number of subjects: 20
Study 29884132 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-OTSA-101 (Arm B: 1110 MBq)
Number of subjects: 20
Study 29884132 — intervention group
Group type: COMPARATOR
Intervention: 90Y-OTSA-101
Number of subjects: 20
Study 26908407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cardiopulmonary bypass arteries
Number of subjects: 12
Study 26908407 — intervention group
Group type: COMPARATOR
Intervention: Post-cardiopulmonary bypass arteries
Number of subjects: 12
Study 26908407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cardiopulmonary bypass biopsies
Number of subjects: 12
Study 26908407 — intervention group
Group type: COMPARATOR
Intervention: Post-cardiopulmonary bypass biopsies
Number of subjects: 12
Study 24529697 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation triage (direct triage on self-sample by methylation analysis of MAL and miR-124-2 genes)
Number of subjects: 1024
Study 24529697 — intervention group
Group type: COMPARATOR
Intervention: Cytology triage (triage by cytology on an additional physician-taken smear)
Number of subjects: 1024
Study 24529697 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation triage
Number of subjects: 1024
Study 24529697 — intervention group
Group type: COMPARATOR
Intervention: Cytology triage
Number of subjects: 1024
Study 22709952 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal inactivated trivalent influenza vaccine (TIV)
Number of subjects: 3697
Study 22709952 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 3697
Study 20647082 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating microscope
Number of subjects: 96
Study 18524542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35
Study 18524542 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 35
Study 16014854 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TRM/SMX)
Number of subjects: 45
Study 12422922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroidinum 30cH
Number of subjects: 208
Study 12422922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 10614792 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (recombinant tissue-type plasminogen activator)
Number of subjects: 45925
Study 10614792 — intervention group
Group type: COMPARATOR
Intervention: PTCA (primary percutaneous transluminal coronary angioplasty)
Number of subjects: 45925
Study 7862180 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (80 units)
Number of subjects: 21
Study 7862180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1951002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg)
Number of subjects: 20
Study 1951002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (400 mg)
Number of subjects: 20
Study 7096998 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine, administered in 0.1 ml volumes intradermally (i.d.) or as 1.0 ml intramuscularly (i.m.)
Number of subjects: 194
Study 7096998 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of human diploid cell rabies vaccine
Number of subjects: 194
Study 7096998 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses administered by the subcutaneous (s.c.) or i.d. route
Number of subjects: 194
Study 7096998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) immunization
Number of subjects: 194
Study 30417737 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vein-graft harvesting
Number of subjects: 1150
Study 30417737 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic vein-graft harvesting
Number of subjects: 1150
Study 29132250 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pilates exercise program
Number of subjects: 80
Study 29132250 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education classes
Number of subjects: 80
Study 27787269 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 2 mg/cm
Number of subjects: 83
Study 27787269 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and injectable lidocaine
Number of subjects: 83
Study 27787269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and loratadine
Number of subjects: 83
Study 27787269 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 treatment
Number of subjects: 83
Study 27787269 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable lidocaine with epinephrine
Number of subjects: 83
Study 24928587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard ED management
Number of subjects: 40
Study 24928587 — intervention group
Group type: COMPARATOR
Intervention: Standard ED management alone
Number of subjects: 40
Study 22003214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (25 mL) injected cephalad to the peroneal-tibial division (Group A)
Number of subjects: 102
Study 22003214 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75% (25 mL) injected caudad to the peroneal-tibial division (Group B)
Number of subjects: 102
Study 19095838 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 139
Study 19095838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra perilaryngeal airway (CobraPLA)
Number of subjects: 139
Study 19095838 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction (LTS)
Number of subjects: 139
Study 16718399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 30
Study 16718399 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study 12540117 — intervention group
Group type: COMPARATOR
Intervention: Hybrid resin composite (Z100)
Number of subjects: 20
Study 12540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow)
Number of subjects: 20
Study 12540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow) + Hybrid resin composite (Z100); light cured separately
Number of subjects: 20
Study 12540117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Filtek Flow) + Hybrid resin composite (Z100); co-cured
Number of subjects: 20
Study 10941879 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (3 g/d)
Number of subjects: 17
Study 10941879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 17
Study 8792787 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on performance
Number of subjects: 16
Study 8792787 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of guidelines and review criteria
Number of subjects: 16
Study 8792787 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions taken in response to interventions
Number of subjects: 16
Study 1464274 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow discontinuation of antiepileptic drugs (AEDs)
Number of subjects: 0
Study 1464274 — intervention group
Group type: COMPARATOR
Intervention: Routine maintenance of antiepileptic drugs (AEDs)
Number of subjects: 0
Study 6389040 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyadenylic‐polyuridylic acid
Number of subjects: 300
Study 6389040 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study 31880760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic transcranial magnetic stimulation
Number of subjects: 55
Study 28641407 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 100
Study 28641407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day and atorvastatin 20 mg/day
Number of subjects: 100
Study 25621239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal splints after PIT (Group A)
Number of subjects: 100
Study 25621239 — intervention group
Group type: COMPARATOR
Intervention: No intranasal splints after PIT (Group B)
Number of subjects: 100
Study 23504926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AER)
Number of subjects: 31
Study 23504926 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 31
Study 23504926 — intervention group
Group type: COMPARATOR
Intervention: Both AER and RES
Number of subjects: 31
Study 21674711 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI scores calculated for symptomatic recurrence
Number of subjects: 93
Study 21674711 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI scores calculated for asymptomatic subjects
Number of subjects: 93
Study 21674711 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI scores compared to endoscopic appearance using the Rutgeerts score
Number of subjects: 93
Study 21674711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of symptom assessment plus endoscopic evidence of recurrence
Number of subjects: 93
Study 19506137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 10
Study 19506137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 10
Study 19506137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride solution infusion)
Number of subjects: 10
Study 19506137 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 10
Study 16469978 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA diet)
Number of subjects: 162
Study 16469978 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA diet)
Number of subjects: 162
Study 16469978 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.6 g n‐3 fatty acids/d)
Number of subjects: 162
Study 14769089 — intervention group
Group type: COMPARATOR
Intervention: Subliminal evaluative conditioning (pairing the word 'I' with positive trait terms)
Number of subjects: 5
Study 14769089 — intervention group
Group type: COMPARATOR
Intervention: Subliminal evaluative conditioning
Number of subjects: 5
Study 11685167 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1 g/d intravenously for 48 hours, then 400 mg/d orally until discharge)
Number of subjects: 102
Study 11685167 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (1 mg intravenously every 6 hours for 48 hours, then 20 mg orally four times a day until discharge)
Number of subjects: 102
Study 11685167 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 102
Study 11685167 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 102
Study 9799348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (100 mg by intramuscular injection)
Number of subjects: 12
Study 9799348 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg by intramuscular injection)
Number of subjects: 12
Study 8306277 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy
Number of subjects: 0
Study 3180632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (3 mg oral and intravenous doses)
Number of subjects: 10
Study 30287523 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily
Number of subjects: 319
Study 30287523 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab IV
Number of subjects: 319
Study 27813670 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) intervention
Number of subjects: 200
Study 27813670 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients without SDM)
Number of subjects: 200
Study 26107742 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent mandatory ventilation (S-NIMV)
Number of subjects: 14
Study 26107742 — intervention group
Group type: COMPARATOR
Intervention: Nonsynchronized nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 14
Study 23954210 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate office‐based probing within two weeks (n = 31)
Number of subjects: 57
Study 23954210 — intervention group
Group type: COMPARATOR
Intervention: Observation and deferred facility probing (n = 26)
Number of subjects: 57
Study 21123460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) enriched in monounsaturated fatty acids
Number of subjects: 20
Study 21123460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 20
Study 18573697 — intervention group
Group type: EXPERIMENTAL
Intervention: SNaPshot technique for fetal genotyping of paternal mutation in maternal blood
Number of subjects: 3
Study 16781967 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention
Number of subjects: 319
Study 16781967 — intervention group
Group type: COMPARATOR
Intervention: Print-based physical activity intervention
Number of subjects: 319